Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, 02114, USA.
Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, 02114, USA; Institute of Ophthalmology, University College London, London, UK.
Ocul Surf. 2019 Apr;17(2):198-207. doi: 10.1016/j.jtos.2019.01.006. Epub 2019 Jan 26.
The therapeutic potential of mesenchymal stem cells (MSCs) has been heralded by their multipotentiality and immunomodulatory capacity. MSCs migrate toward sites of tissue damage, where specific pro-inflammatory factors 'license' their immunosuppressive functions. Recent studies in animal models of ocular surface disease have demonstrated the potential of MSC-derived therapies to limit inflammation and promote tissue repair. Herein, we review the immunoregulatory mechanisms of MSCs, as well as strategies to harness their regenerative function at the cornea. We examine reports of the therapeutic application of MSCs in the setting of ocular surface inflammation; including corneal injury, transplantation, ocular surface autoimmunity and allergy.
间充质干细胞 (MSCs) 的治疗潜力因其多能性和免疫调节能力而备受关注。MSCs 向组织损伤部位迁移，在那里特定的促炎因子“许可”其免疫抑制功能。最近在眼表疾病的动物模型中进行的研究表明，MSC 衍生疗法具有限制炎症和促进组织修复的潜力。本文综述了 MSCs 的免疫调节机制，以及在角膜中利用其再生功能的策略。我们检查了 MSCs 在眼表炎症环境中的治疗应用报告；包括角膜损伤、移植、眼表自身免疫和过敏。
